These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

464 related articles for article (PubMed ID: 11444652)

  • 21. Comparison in patients with type 2 diabetes of fibric acid versus hepatic hydroxymethyl glutaryl-coenzyme a reductase inhibitor treatment of combined dyslipidemia.
    McLaughlin T; Abbasi F; Lamendola C; Leary E; Reaven GM
    Metabolism; 2002 Oct; 51(10):1355-9. PubMed ID: 12370858
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Effects of modifying triglycerides and triglyceride-rich lipoproteins on cardiovascular outcomes.
    Abdel-Maksoud M; Sazonov V; Gutkin SW; Hokanson JE
    J Cardiovasc Pharmacol; 2008 Apr; 51(4):331-51. PubMed ID: 18427276
    [TBL] [Abstract][Full Text] [Related]  

  • 23. [HDL, or non-HDL: that is the question. Possibilities of pharmacological treatment in residual dyslipidaemia].
    Bajnok L
    Orv Hetil; 2014 Jan; 155(2):62-8. PubMed ID: 24389322
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Medical lipid-regulating therapy: current evidence, ongoing trials and future developments.
    Evans M; Roberts A; Davies S; Rees A
    Drugs; 2004; 64(11):1181-96. PubMed ID: 15161326
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Management of hypercholesterolaemia in postmenopausal women.
    Davidson MH; Maki KC; Karp SK; Ingram KA
    Drugs Aging; 2002; 19(3):169-78. PubMed ID: 12027776
    [TBL] [Abstract][Full Text] [Related]  

  • 26. The rationale for combination therapy.
    Rosenson RS
    Am J Cardiol; 2002 Nov; 90(10B):2K-7K. PubMed ID: 12467935
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Is there evidence-based hypolipidemic treatment with clinical benefit beyond statins?
    Goumas GS
    Angiology; 2009; 60(1):93-8. PubMed ID: 19019838
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Dyslipidaemia: cardiovascular prevention--end of the road for niacin?
    Tuteja S; Rader DJ
    Nat Rev Endocrinol; 2014 Nov; 10(11):646-7. PubMed ID: 25178730
    [TBL] [Abstract][Full Text] [Related]  

  • 29. [Efficacy and safety of combined statin-fenofibrates therapy compared with monotherapy in patients with mixed hyperlipidemia and high risk of coronary heart disease].
    Kłosiewicz-Latoszek L; Respondek W; Białobrzeska-Paluszkiewicz J; Grzybowska B; Jakóbisiak-Ostasz B; Stolarska I
    Pol Merkur Lekarski; 2003 Jul; 15(85):42-6. PubMed ID: 14593958
    [TBL] [Abstract][Full Text] [Related]  

  • 30. The triglyceride-high-density lipoprotein axis: an important target of therapy?
    Szapary PO; Rader DJ
    Am Heart J; 2004 Aug; 148(2):211-21. PubMed ID: 15308990
    [TBL] [Abstract][Full Text] [Related]  

  • 31. [Diabetic dyslipidaemia and the atherosclerosis].
    Márk L; Dani G
    Orv Hetil; 2016 May; 157(19):746-52. PubMed ID: 27133274
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Effectiveness of aggressive management of dyslipidemia in a collaborative-care practice model.
    Ryan MJ; Gibson J; Simmons P; Stanek E
    Am J Cardiol; 2003 Jun; 91(12):1427-31. PubMed ID: 12804728
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Raising low levels of high-density lipoprotein cholesterol is an important target of therapy.
    Boden WE; Pearson TA
    Am J Cardiol; 2000 Mar; 85(5):645-50, A10. PubMed ID: 11078282
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Raising high-density lipoprotein cholesterol with niacin and fibrates: a comparative review.
    Sprecher DL
    Am J Cardiol; 2000 Dec; 86(12A):46L-50L. PubMed ID: 11374856
    [TBL] [Abstract][Full Text] [Related]  

  • 35. An exploratory study examining lipid-lowering medications in reducing fasting serum lipids in schizophrenia patients treated with atypical antipsychotics.
    Vincenzi B; Borba CP; Gray DA; Copeland PM; Wang X; Fan X; Aragam GG; Henderson DC
    Ann Clin Psychiatry; 2013 May; 25(2):141-8. PubMed ID: 23638445
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Managing diabetic dyslipidemia: beyond statin therapy.
    Neeli H; Gadi R; Rader DJ
    Curr Diab Rep; 2009 Feb; 9(1):11-7. PubMed ID: 19192419
    [TBL] [Abstract][Full Text] [Related]  

  • 37. New developments in the use of niacin for treatment of hyperlipidemia: new considerations in the use of an old drug.
    Crouse JR
    Coron Artery Dis; 1996 Apr; 7(4):321-6. PubMed ID: 8853585
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Targeting cardiovascular risk associated with both low density and high density lipoproteins using statin-niacin combination therapy.
    Duvall WL; Blazing MA; Saxena S; Guyton JR
    J Cardiovasc Risk; 2002 Dec; 9(6):339-47. PubMed ID: 12478203
    [TBL] [Abstract][Full Text] [Related]  

  • 39. The facts behind niacin.
    Hochholzer W; Berg DD; Giugliano RP
    Ther Adv Cardiovasc Dis; 2011 Oct; 5(5):227-40. PubMed ID: 21893559
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Antiatherothrombotic effects of nicotinic acid.
    Rosenson RS
    Atherosclerosis; 2003 Nov; 171(1):87-96. PubMed ID: 14642410
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 24.